Free Trial
OTCMKTS:SGIOY

Shionogi & Co., Ltd. (SGIOY) Stock Price, News & Analysis

Shionogi & Co., Ltd. logo
$7.14
-0.01 (-0.14%)
(As of 11/4/2024 ET)

About Shionogi & Co., Ltd. Stock (OTCMKTS:SGIOY)

Key Stats

Today's Range
$6.96
$7.43
50-Day Range
$6.75
$11.61
52-Week Range
$6.22
$9.11
Volume
207,561 shs
Average Volume
146,282 shs
Market Capitalization
$12.70 billion
P/E Ratio
12.17
Dividend Yield
1.68%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Shionogi & Co., Ltd. Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
28th Percentile Overall Score

SGIOY MarketRank™: 

Shionogi & Co., Ltd. scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Shionogi & Co., Ltd. are expected to remain at $0.26 per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Shionogi & Co., Ltd. is 12.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.10.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Shionogi & Co., Ltd. is 12.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.16.

  • Price to Earnings Growth Ratio

    Shionogi & Co., Ltd. has a PEG Ratio of 5.59. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Shionogi & Co., Ltd. has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Shionogi & Co., Ltd. have been sold short.
  • Short Interest Ratio / Days to Cover

    Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Shionogi & Co., Ltd. has recently increased by 120.34%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Shionogi & Co., Ltd. pays a meaningful dividend of 1.67%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Shionogi & Co., Ltd. does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Shionogi & Co., Ltd. is 20.34%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Shionogi & Co., Ltd. will have a dividend payout ratio of 46.15% next year. This indicates that Shionogi & Co., Ltd. will be able to sustain or increase its dividend.

  • Read more about Shionogi & Co., Ltd.'s dividend.
  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Shionogi & Co., Ltd. have been sold short.
  • Short Interest Ratio / Days to Cover

    Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Shionogi & Co., Ltd. has recently increased by 120.34%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Shionogi & Co., Ltd. has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Shionogi & Co., Ltd. this week, compared to 0 articles on an average week.
Receive SGIOY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. and its competitors with MarketBeat's FREE daily newsletter.

SGIOY Stock News Headlines

[Urgent] Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
Jefferies Sticks to Its Hold Rating for Shionogi & Co (SGIOF)
Shionogi & Co., Ltd. (4507.T)
SGIOF Shionogi & Co., Ltd.
Shionogi earnings preview: what to expect
See More Headlines

SGIOY Stock Analysis - Frequently Asked Questions

Shionogi & Co., Ltd.'s stock was trading at $11.9720 at the beginning of the year. Since then, SGIOY stock has decreased by 40.4% and is now trading at $7.14.
View the best growth stocks for 2024 here
.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) posted its earnings results on Wednesday, January, 31st. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.33 by $0.11. The company had revenue of $719.72 million for the quarter. Shionogi & Co., Ltd. had a trailing twelve-month return on equity of 11.95% and a net margin of 35.53%.

Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
1/31/2024
Today
11/05/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
Personal Services
Current Symbol
OTCMKTS:SGIOY
Fax
N/A
Employees
5,680
Year Founded
N/A

Profitability

Net Income
$1.12 billion
Pretax Margin
45.57%

Debt

Sales & Book Value

Annual Sales
$3.01 billion
Cash Flow
$0.70 per share
Book Value
$4.86 per share

Miscellaneous

Outstanding Shares
1,779,264,000
Free Float
N/A
Market Cap
$12.70 billion
Optionable
Not Optionable
Beta
0.22
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:SGIOY) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners